{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T04:03:58Z","timestamp":1751256238776,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T00:00:00Z","timestamp":1470700800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["142254"],"award-info":[{"award-number":["142254"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s40273-016-0440-x","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T11:18:49Z","timestamp":1470741529000},"page":"97-109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6612-2332","authenticated-orcid":false,"given":"Paul","family":"Tappenden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Harnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijie","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveen","family":"Thokala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Mukuria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Pledge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Tidy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,9]]},"reference":[{"key":"440_CR1","volume-title":"Guide to the processes of technology appraisal","author":"National Institute for Health and Care Excellence","year":"2014","unstructured":"National Institute for Health and Care Excellence. Guide to the processes of technology appraisal. London: NICE; 2014."},{"key":"440_CR2","volume-title":"Olaparib for maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy: a Single Technology Appraisal","author":"P Tappenden","year":"2015","unstructured":"Tappenden P, Harnan S, Ren S, Thokala P, Wong R, Mukuria C, et al. Olaparib for maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy: a Single Technology Appraisal. Sheffield: University of Sheffield; 2015."},{"key":"440_CR3","doi-asserted-by":"crossref","unstructured":"Tappenden P. Olaparib for maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy: a Single Technology Appraisal. Addendum\u2014analysis of olaparib Patient Access Scheme. Sheffield: University of Sheffield; 2015.","DOI":"10.1007\/s40273-016-0440-x"},{"key":"440_CR4","doi-asserted-by":"crossref","unstructured":"Tappenden P, Harnan S, Ren S. Olaparib for maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy: a Single Technology Appraisal. Addendum\u2014ERG comments on the company\u2019s response to the ACD. Sheffield: University of Sheffield; 2015.","DOI":"10.1007\/s40273-016-0440-x"},{"key":"440_CR5","doi-asserted-by":"crossref","unstructured":"Tappenden P, Harnan S, Bermejo I. Olaparib for maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy: a Single Technology Appraisal. Addendum\u2014ERG critique of company\u2019s response to ACD2. Sheffield: University of Sheffield; 2015.","DOI":"10.1007\/s40273-016-0440-x"},{"key":"440_CR6","unstructured":"National Institute for Health and Care Excellence. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy. Technology Appraisal Guidance 381. London: NICE; 2016."},{"key":"440_CR7","unstructured":"National Institute for Health and Care Excellence. Ovarian cancer: recognition and initial management. Clinical guideline 122. London: NICE; 2011."},{"key":"440_CR8","unstructured":"Cancer Research UK. Ovarian cancer statistics. 2016. Available from: http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/ovarian-cancer . Accessed 01 May 2016."},{"key":"440_CR9","doi-asserted-by":"crossref","unstructured":"Poonawalla IB, Parikh RC, Du XL, VonVille HM, Lairson DR. Cost effectiveness of chemotherapeutic agents and targeted biologics in ovarian cancer: a systematic review. Pharmacoecnomics. 2015;33(11):1155\u201385.","DOI":"10.1007\/s40273-015-0304-9"},{"issue":"9747","key":"440_CR10","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","volume":"376","author":"GJ Rustin","year":"2010","unstructured":"Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155\u201363.","journal-title":"Lancet"},{"key":"440_CR11","unstructured":"National Institute for Health and Care Excellence. Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer. Technology Appraisal Guidance 91. London: NICE; 2005."},{"key":"440_CR12","volume-title":"Summary of product characteristics\u2014olaparib","author":"European Medicines Agency","year":"2015","unstructured":"European Medicines Agency. Summary of product characteristics\u2014olaparib. London: EMA; 2015."},{"key":"440_CR13","unstructured":"BMJ Group, RCPCH Publications Ltd and the Royal Pharmaceutical Society of Great Britain. British National Formulary; 2014."},{"key":"440_CR14","unstructured":"AstraZeneca UK Ltd. Olaparib as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed (PSR) BRCA-mutated (germline and\/or somatic) high-grade, serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy. Single Technology Appraisal. Manufacturer\u2019s submission to the National Institute for Health and Care Excellence. Luton: AstraZeneca; 2015."},{"key":"440_CR15","unstructured":"National Institute for Health and Care Excellence. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. Clinical Guideline 164. London: NICE; 2013."},{"key":"440_CR16","volume-title":"Olaparib for maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy\u2014final scope","author":"National Institute for Health and Care Excellence","year":"2014","unstructured":"National Institute for Health and Care Excellence. Olaparib for maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy\u2014final scope. London: NICE; 2014."},{"key":"440_CR17","unstructured":"AstraZeneca UK Ltd. Olaparib as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed (PSR) BRCA-mutated (germline and\/or somatic) high-grade, serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy. Single Technology Appraisal. Response to clarification questions. Luton: AstraZeneca; 2015."},{"issue":"15","key":"440_CR18","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382\u201392.","journal-title":"N Engl J Med"},{"key":"440_CR19","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda: NCI; 2006."},{"issue":"8","key":"440_CR20","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852\u201361.","journal-title":"Lancet Oncol"},{"key":"440_CR21","unstructured":"AstraZenecca Ltd. Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or more platinum containing regimens. Macclesfield: AstraZeneca; 2015."},{"key":"440_CR22","volume-title":"Committee for Medicinal Products for Human Use (CHMP)\u2014assessment report\u2014olaparib","author":"European Medicines Agency","year":"2014","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP)\u2014assessment report\u2014olaparib. London: EMA; 2014."},{"key":"440_CR23","volume-title":"Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer following response to second-line or subsequent platinum-based chemotherapy. Appraisal Consultation Document","author":"National Institute for Health and Care Excellence","year":"2015","unstructured":"National Institute for Health and Care Excellence. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer following response to second-line or subsequent platinum-based chemotherapy. Appraisal Consultation Document. London: NICE; 2015."},{"key":"440_CR24","doi-asserted-by":"crossref","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Health-related quality of life (HRQoL) during olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) and a BRCA mutation (BRCAm). In: European Society for Medical Oncology Madrid, Spain, 26\u201330 September 2014.","DOI":"10.1093\/annonc\/mdu338.11"},{"key":"440_CR25","volume-title":"Guideline on the evaluation of anticancer medicinal products in man","author":"European Medicines Agency","year":"2015","unstructured":"European Medicines Agency. Guideline on the evaluation of anticancer medicinal products in man. London: EMA; 2015."},{"key":"440_CR26","volume-title":"Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care","author":"Centre for Reviews and Dissemination","year":"2009","unstructured":"Centre for Reviews and Dissemination. Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care. York: University of York; 2009."},{"key":"440_CR27","doi-asserted-by":"crossref","unstructured":"Longworth L, Yang Y, Young T, Mulhern B, Hernandez Alava M, Mukuria C. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess. 2014;18(9):i-224.","DOI":"10.3310\/hta18090"},{"key":"440_CR28","unstructured":"National Institute for Health and Care Excellence. Trabectedin for the treatment of relapsed ovarian cancer. Technology Appraisal Guidance 222. London: NICE; 2011."},{"key":"440_CR29","unstructured":"National Institute for Health and Care Excellence. Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer. Technology Appraisal Guidance 285. London: NICE; 2013."},{"issue":"1","key":"440_CR30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2354.2005.00623.x","volume":"15","author":"J Guest","year":"2006","unstructured":"Guest J, Ruiz F, Greener M, Trotman I. Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK. Eur J Cancer Care. 2006;15(1):65\u201373.","journal-title":"Eur J Cancer Care"},{"key":"440_CR31","doi-asserted-by":"crossref","unstructured":"Gao W, Ho Y, Verne J, Glickman M, Higginson I, on behalf of the GUIDE Care Project. Changing patterns in place of cancer death in England: a population-based study. PLoS Med 2013;10(3).","DOI":"10.1371\/journal.pmed.1001410"},{"key":"440_CR32","volume-title":"Epithelial ovarian carcinoma\u20142nd and subsequent line","author":"Yorkshire Cancer Network Gynaecology Network Group","year":"2010","unstructured":"Yorkshire Cancer Network Gynaecology Network Group. Epithelial ovarian carcinoma\u20142nd and subsequent line. Leeds: YCNGNG; 2010."},{"key":"440_CR33","volume-title":"NHS reference costs 2013\u201314","author":"Department of Health","year":"2014","unstructured":"Department of Health. NHS reference costs 2013\u201314. London: DH; 2014."},{"key":"440_CR34","volume-title":"Unit costs of health and social care","author":"L Curtis","year":"2013","unstructured":"Curtis L. Unit costs of health and social care. Kent: Personal Social Services Research Unit; 2013."},{"key":"440_CR35","volume-title":"Drugs and pharmaceutical electronic market information (eMit)","author":"Department of Health Commercial Medicines Unit","year":"2014","unstructured":"Department of Health Commercial Medicines Unit. Drugs and pharmaceutical electronic market information (eMit). London: DH; 2014."},{"key":"440_CR36","volume-title":"Guide to the methods of technology appraisal","author":"National Institute for Health and Care Excellence","year":"2013","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. London: NICE; 2013."},{"key":"440_CR37","volume-title":"NICE DSU Technical Support Document 14: Survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data","author":"N Latimer","year":"2013","unstructured":"Latimer N. NICE DSU Technical Support Document 14: Survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data. Sheffield: University of Sheffield; 2013."},{"key":"440_CR38","doi-asserted-by":"crossref","unstructured":"Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves. BMC Med Res Methodol 2011;12(9).","DOI":"10.1186\/1471-2288-12-9"},{"key":"440_CR39","unstructured":"AstraZeneca UK Ltd. Olaparib as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed (PSR) BRCA-mutated (germline and\/or somatic) high-grade, serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy. Single Technology Appraisal. Response to ACD. Luton; AstraZeneca; 2015."},{"key":"440_CR40","unstructured":"AstraZeneca UK Ltd. Olaparib as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed (PSR) BRCA-mutated (germline and\/or somatic) high-grade, serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy. Single Technology Appraisal. Response to second ACD. Luton: AstraZeneca; 2015."},{"key":"440_CR41","volume-title":"Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy. Final Appraisal Determination","author":"National Institute for Health and Care Excellence","year":"2016","unstructured":"National Institute for Health and Care Excellence. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy. Final Appraisal Determination. London: NICE; 2016."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-016-0440-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-016-0440-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-016-0440-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-016-0440-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T23:22:52Z","timestamp":1600989772000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-016-0440-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,9]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["440"],"URL":"https:\/\/doi.org\/10.1007\/s40273-016-0440-x","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2016,8,9]]}}}